Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tissue characteristics underlying endocardial local impedance subtypes in chronic myocardial infarction

  • Aranyó, Júlia
  • Martínez-Falguera, Daina|||0000-0002-9439-0542
  • Teis, Albert|||0000-0002-4820-0736
  • Fadeuilhe, Edgar|||0000-0003-0079-224X
  • Rodriguez-Leor, Oriol|||0000-0003-2657-5657
  • Bazán, Víctor|||0000-0001-8072-7434
  • Sarrias, Axel|||0000-0001-6712-3097
  • Tebé, Cristian|||0000-0003-2320-1385
  • Villuendas-Sabaté, Roger|||0000-0001-9110-905X
  • Delgado, Victoria|||0000-0002-9841-2737
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Bisbal, Felipe|||0000-0002-4843-7063
Background: Local impedance (LI) mapping is feasible and provides additional tissue characterization of the ventricular tachycardia substrate. Data on tissue composition underlying the LI spectrum are lacking. Objective: To describe the tissue composition underlying different LI subtypes in a chronic myocardial infarction (MI) swine model. Methods: One month after non-reperfused anterior MI, 18 Landrace Large White pigs underwent delayed-enhancement cardiac magnetic resonance (DE-CMR) and endocardial left ventricular (LV) LI mapping. DE-CMR images were post-processed off-line to obtain LV wall thickness, scar subtypes, and border zone (BZ) corridors, and were co-registered with LI maps. Tissue samples were obtained from abnormal LI sites. Results: Low LI zones exhibited more pronounced wall thinning compared to intermediate LI tissue (2.8 ± 0.7 vs 3.8 ± 0.9 mm; P <.001) and correlated with DE-CMR dense endocardial scarring (91.4%) and with epicardial scarring (75% dense and 24% BZ tissue). Intermediate LI tissue exhibited predominantly subendocardial scarring, with more heterogeneous distribution (45% dense, 47% BZ, and 8% healthy tissue) and less epicardial involvement (73% healthy tissue). Most DE-CMR BZ corridors (75.6%) colocalized with intermediate LI tissue. Histologically, tissue from intermediate LI zones displayed less collagen I (P =.008), collagen III (P =.053), and collagen volume fraction (P =.021), and greater vascular density (P =.075), compared to low LI zones. Conclusions: Areas of low LI had a higher proportion of dense, transmural scar and wall thinning compared to intermediate LI areas. DE-CMR BZ corridors colocalized with intermediate LI in most cases. LI subtypes showed distinctive histological composition.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A narrative review of vascular conduits for coronary artery bypass grafting

  • Iraola-Picornell, Georgina
  • Berastegui García, Elisabet|||0000-0002-1766-2970
  • Castells-Sala, Cristina|||0000-0002-7520-5401
  • Martorell, Jordi|||0000-0002-2043-2762
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Muñoz-Guijosa, Christian|||0000-0002-0272-1704
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
Coronary artery bypass grafting (CABG) involves creating new conduits to restore blood flow to the heart. Using autologous vascular grafts presents challenges, including infection risk after vein harvesting, and scarcity of viable vein tissue. Researchers are exploring tissue-engineered vascular grafts (TEVGs), aiming to create optimal small-diameter vascular graft (SDVG).
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

A narrative review of vascular conduits for coronary artery bypass grafting

  • Iraola, Georgina
  • Berastegui, Elisabet
  • Castells-Sala, Cristina
  • Martorell, Jordi
  • Bayes-Genis, Antoni
  • Muñoz-Guijosa, Christian
  • Gálvez-Montón, Carolina
Coronary artery bypass grafting (CABG) involves creating new conduits to restore blood flow to the heart. Using autologous vascular grafts presents challenges, including infection risk after vein harvesting, and scarcity of viable vein tissue. Researchers are exploring tissue-engineered vascular grafts (TEVGs), aiming to create optimal small-diameter vascular graft (SDVG) (<6 mm) for CABG surgery. TEVGs with suitable long-term patency could offer a promising alternative, potentially reduce patient morbidity and improve surgical outcomes. However, no SDVG is commercially available for CABG surgery in Europe, and no new clinical trials of coronary TEVGs have been reported since 2018. This narrative review summarizes the development and use of SDVG (<6 mm) for CABG, focusing on TEVGs and cell-seeding strategies. We outline the main types of grafts tested in preclinical and early clinical studies and highlight how different cell sources and seeding approaches aim to enhance graft functionality, patency, and long-term outcome., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A narrative review of vascular conduits for coronary artery bypass grafting

  • Iraola, Georgina
  • Berastegui, Elisabet
  • Castells-Sala, Cristina
  • Martorell, Jordi
  • Bayes-Genis, Antoni
  • Muñoz-Guijosa, Christian
  • Gálvez-Montón, Carolina
Coronary artery bypass grafting (CABG) involves creating new conduits to restore blood flow to the heart. Using autologous vascular grafts presents challenges, including infection risk after vein harvesting, and scarcity of viable vein tissue. Researchers are exploring tissue-engineered vascular grafts (TEVGs), aiming to create optimal small-diameter vascular graft (SDVG) (<6 mm) for CABG surgery. TEVGs with suitable long-term patency could offer a promising alternative, potentially reduce patient morbidity and improve surgical outcomes. However, no SDVG is commercially available for CABG surgery in Europe, and no new clinical trials of coronary TEVGs have been reported since 2018. This narrative review summarizes the development and use of SDVG (<6 mm) for CABG, focusing on TEVGs and cell-seeding strategies. We outline the main types of grafts tested in preclinical and early clinical studies and highlight how different cell sources and seeding approaches aim to enhance graft functionality, patency, and long-term outcome., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Implantation of a double allogeneic human engineered tissue graft on damaged heart, insights from the PERISCOPE phase I clinical trial

  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Gastelurrutia, Paloma|||0000-0001-6974-9210
  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Cámara, Maria-Luisa|||0000-0002-5204-1459
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Cediel, Germán|||0000-0001-9667-7507
  • Rodríguez Gómez, Luciano
  • Teis, Albert|||0000-0002-4820-0736
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Ferrer-Curriu, Gemma|||0000-0002-2651-649X
  • Roura, Santiago|||0000-0003-4063-9661
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Bisbal, Felipe|||0000-0002-4843-7063
  • Vives Armengol, Joaquim|||0000-0001-9719-5235
  • Vilarrodona, Ana|||0000-0001-6984-1834
  • Muñoz-Guijosa, Christian|||0000-0002-0272-1704
  • Querol, Sergi|||0000-0002-1105-8633
Background: In preclinical studies, the use of double allogeneic grafts has shown promising results in promoting tissue revascularization, reducing infarct size, preventing adverse remodelling and fibrosis, and ultimately enhancing cardiac function. Building upon these findings, the safety of PeriCord, an engineered tissue graft consisting of a decellularised pericardial matrix and umbilical cord Wharton's jelly mesenchymal stromal cells, was evaluated in the PERISCOPE Phase I clinical trial (NCT03798353), marking its first application in human subjects. Methods: This was a double-blind, single-centre trial that enrolled patients with non-acute myocardial infarction eligible for surgical revascularization. Seven patients were implanted with PeriCord while five served as controls. Findings: Patients who received PeriCord showed no adverse effects during post-operative phase and one-year follow-up. No significant changes in secondary outcomes, such as quality of life or cardiac function, were found in patients who received PeriCord. However, PeriCord did modulate the kinetics of circulating monocytes involved in post-infarction myocardial repair towards non-classical inflammation-resolving macrophages, as well as levels of monocyte chemoattractants and the prognostic marker Meteorin-like in plasma following treatment. Interpretation: In summary, the PeriCord graft has exhibited a safe profile and notable immunomodulatory properties. Nevertheless, further research is required to fully unlock its potential as a platform for managing inflammatory-related pathologies.